Top

Published in:

Open Access 01-03-2019

Structural and functional abnormalities in iron-depleted heart

Authors: Kamil A Kobak, Malwina Radwańska, Magdalena Dzięgała, Monika Kasztura, Krystian Josiak, Waldemar Banasiak, Piotr Ponikowski, Ewa A Jankowska

Published in: Heart Failure Reviews | Issue 2/2019

Abstract

Iron deficiency (ID) is a common and ominous comorbidity in heart failure (HF) and predicts worse outcomes, independently of the presence of anaemia. Accumulated data from animal models of systemic ID suggest that ID is associated with several functional and structural abnormalities of the heart. However, the exact role of myocardial iron deficiency irrespective of systemic ID and/or anaemia has been elusive. Recently, several transgenic models of cardiac-specific ID have been developed to investigate the influence of ID on cardiac tissue. In this review, we discuss structural and functional cardiac consequences of ID in these models and summarize data from clinical studies. Moreover, the beneficial effects of intravenous iron supplementation are specified.

Abbaspour N, Hurrell R, Kelishadi R (2014) Review on iron and its importance for human health. J Res Med Sci 19:164–174PubMedPubMedCentral

Stehling O, Lill R (2013) The role of mitochondria in cellular Iron-sulfur protein biogenesis: mechanisms, connected processes, and diseases. Cold Spring Harb Perspect Biol 5:a011312–a011312. https://doi.org/10.1101/cshperspect.a011312 CrossRefPubMedPubMedCentral

Zannad F (2014) Co-morbidities in heart failure, an issue of heart failure clinics. E-Book, Elsevier Health Sciences

Stugiewicz M, Tkaczyszyn M, Kasztura M, Banasiak W, Ponikowski P, Jankowska EA (2016) The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. Eur J Heart Fail 18:762–773. https://doi.org/10.1002/ejhf.467 CrossRefPubMed

Jankowska EA, Kasztura M, Sokolski M, Bronisz M, Nawrocka S, Oleśkowska-Florek W, Zymliński R, Biegus J, Siwołowski P, Banasiak W, Anker SD, Filippatos G, Cleland JGF, Ponikowski P (2014) Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J 35:2468–2476. https://doi.org/10.1093/eurheartj/ehu235 CrossRefPubMed

Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P (2013) Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 34:816–829. https://doi.org/10.1093/eurheartj/ehs224 CrossRefPubMed

Klip IT, Comin-Colet J, Voors AA et al (2013) Iron deficiency in chronic heart failure: An international pooled analysis. Am Heart J 165:575–582.e3. https://doi.org/10.1016/j.ahj.2013.01.017 CrossRefPubMed

Okonko DO, Mandal AKJ, Missouris CG, Poole-Wilson PA (2011) Disordered Iron homeostasis in chronic heart failure. J Am Coll Cardiol 58:1241–1251. https://doi.org/10.1016/j.jacc.2011.04.040 CrossRefPubMed

van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC (2011) Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 8:485–493. https://doi.org/10.1038/nrcardio.2011.77 CrossRefPubMed

10.

McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B (2009) Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993–2005. Public Health Nutr 12:444. https://doi.org/10.1017/S1368980008002401 CrossRefPubMed

11.

Flanagan PR, Haist J, Valberg LS (1980) Comparative effects of iron deficiency induced by bleeding and a low-iron diet on the intestinal absorptive interactions of iron, cobalt, manganese, zinc, lead and cadmium. J Nutr 110:1754–1763CrossRefPubMed

12.

Nagababu E, Gulyani S, Earley CJ, Cutler RG, Mattson MP, Rifkind JM (2008) Iron-deficiency anaemia enhances red blood cell oxidative stress. Free Radic Res 42:824–829. https://doi.org/10.1080/10715760802459879 CrossRefPubMedPubMedCentral

13.

Toblli JE, Cao G, Rivas C, Giani JF, Dominici FP (2016) Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative/nitrosative stress and inflammation. Int J Cardiol 212:84–91. https://doi.org/10.1016/j.ijcard.2016.03.039 CrossRefPubMed

14.

Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuyama T (2009) Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 296:H585–H593. https://doi.org/10.1152/ajpheart.00463.2008 CrossRefPubMed

15.

Olivetti G, Quaini F, Lagrasta C, et al (1992) Myocyte Cellular Hypertrophy and Hyperplasia Contribute to Ventricular Wall Remodeling in Anemia-induced Cardiac Hypertrophy in Rats Am J Pathol 141:

16.

Tanne Z, Coleman R, Nahir M, Shomrat D, Finberg JPM, Youdim MBH (1994) Ultrastructural and cytochemical changes in the heart of iron-deficient rats. Biochem Pharmacol 47:1759–1766. https://doi.org/10.1016/0006-2952(94)90303-4 CrossRefPubMed

17.

Medeiros DM, Beard JL (1998) Dietary iron deficiency results in cardiac eccentric hypertrophy in rats. Proc Soc Exp Biol Med 218(4):370–375CrossRefPubMed

18.

Maeder MT, Khammy O, dos Remedios C, Kaye DM (2011) Myocardial and systemic Iron depletion in heart failure: implications for Anemia accompanying heart failure. J Am Coll Cardiol 58:474–480. https://doi.org/10.1016/J.JACC.2011.01.059 CrossRefPubMed

19.

Anand IS, Gupta P (2018) Anemia and Iron deficiency in heart failure. Circulation 138:80–98. https://doi.org/10.1161/CIRCULATIONAHA.118.030099 CrossRefPubMed

20.

Turner LR, Premo DA, Gibbs BJ, Hearthway ML, Motsko M, Sappington A, Walker LA, Mullendore ME, Chew HG (2002) Adaptations to iron deficiency: cardiac functional responsiveness to norepinephrine, arterial remodeling, and the effect of beta-blockade on cardiac hypertrophy. BMC Physiol 2:1CrossRefPubMedPubMedCentral

21.

Duke M, Abelmann WH (1969) The hemodynamic response to chronic anemia. Circulation 39:503–515CrossRefPubMed

22.

Petering DH, Stemmer KL, Lyman S, et al (1990) Iron deficiency in growing male rats: a cause of development of cardiomyopathy. Ann Nutr Metab 34:(4)232–243. http://www.ncbi.nlm.nih.gov/pubmed/2400205. Accessed September 22, 2017

23.

Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J (2005) Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci 109:277–286. https://doi.org/10.1042/CS20040278 CrossRefPubMed

24.

Tsutsui H, Kinugawa S, Matsushima S (2008) Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 81:449–456. https://doi.org/10.1093/cvr/cvn280 CrossRefPubMed

25.

Nur-E-Kamal A, Gross SR, Pan Z, Balklava Z, Ma J, Liu LF (2004) Nuclear translocation of cytochrome c during apoptosis. J Biol Chem 279:24911–24914. https://doi.org/10.1074/jbc.C400051200 CrossRefPubMed

26.

Gargalovic P, Dory L (2003) Cellular apoptosis is associated with increased caveolin-1 expression in macrophages. J Lipid Res 44:1622–1632. https://doi.org/10.1194/jlr.M300140-JLR200 CrossRefPubMed

27.

Blayney L, Bailey-Wood R, Jacobs A, Henderson A, Muir J (1976) The effects of iron deficiency on the respiratory function and cytochrome content of rat heart mitochondria. Circ Res 39(5):744–748CrossRefPubMed

28.

Ponka P, Lok CN (1999) The transferrin receptor: role in health and disease. Int J Biochem Cell Biol 31:1111–1137CrossRefPubMed

29.

Hentze MW, Muckenthaler MU, Andrews NC (2004) Balancing acts: molecular control of mammalian iron metabolism. Cell 117:285–297CrossRefPubMed

30.

Andrews N, Levy JE, Jin O, Fujiwara Y, Kuo F (1999) Transferrin receptor is necessary for development of erythrocytes and the nervous system. Nat Genet 21:396–399. https://doi.org/10.1038/7727 CrossRefPubMed

31.

Xu W, Barrientos T, Mao L, Rockman HA, Sauve AA, Andrews NC (2015) Lethal cardiomyopathy in mice lacking transferrin receptor in the heart. Cell Rep 13:533–545. https://doi.org/10.1016/j.celrep.2015.09.023 CrossRefPubMedPubMedCentral

32.

Stehling O, Mascarenhas J, Vashisht AA, Sheftel AD, Niggemeyer B, Rösser R, Pierik AJ, Wohlschlegel JA, Lill R (2013) Human CIA2A-FAM96A and CIA2B-FAM96B integrate Iron homeostasis and maturation of different subsets of cytosolic-nuclear Iron-sulfur proteins. Cell Metab 18:187–198. https://doi.org/10.1016/j.cmet.2013.06.015 CrossRefPubMedPubMedCentral

33.

Xu W, Barrientos T, Andrews NC (2013) Iron and copper in mitochondrial diseases. Cell Metab 17:319–328. https://doi.org/10.1016/j.cmet.2013.02.004 CrossRefPubMedPubMedCentral

34.

Ganz T (2005) Cellular iron: Ferroportin is the only way out. Cell Metab 1:155–157. https://doi.org/10.1016/j.cmet.2005.02.005 CrossRefPubMed

35.

Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C (2002) Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet 33:21–22. https://doi.org/10.1038/ng1053 CrossRefPubMed

36.

Nemeth E, Tuttle MS, Powelson J et al (2004) Hepcidin regulates cellular Iron efflux by binding to Ferroportin and inducing its internalization. Science (80- ) 306:2090–2093. https://doi.org/10.1126/science.1104742

37.

Merle U, Fein E, Gehrke SG, Stremmel W, Kulaksiz H (2007) The Iron regulatory peptide Hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 148:2663–2668. https://doi.org/10.1210/en.2006-1331 CrossRefPubMed

38.

Kulaksiz H, Theilig F, Bachmann S, Gehrke SG, Rost D, Janetzko A, Cetin Y, Stremmel W (2005) The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol 184:361–370. https://doi.org/10.1677/joe.1.05729 CrossRefPubMed

39.

McCarthy RC, Kosman DJ (2014) Glial cell Ceruloplasmin and Hepcidin differentially regulate Iron efflux from brain microvascular endothelial cells. PLoS One 9:e89003. https://doi.org/10.1371/journal.pone.0089003 CrossRefPubMedPubMedCentral

40.

Evans P, Cindrova-Davies T, Muttukrishna S, Burton GJ, Porter J, Jauniaux E (2011) Hepcidin and iron species distribution inside the first-trimester human gestational sac. Mol Hum Reprod 17:227–232. https://doi.org/10.1093/molehr/gaq101 CrossRefPubMed

41.

Vela D (2017) Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology. Lab Investig 98:315–326. https://doi.org/10.1038/labinvest.2017.111 CrossRefPubMed

42.

Lakhal-Littleton S, Wolna M, Carr CA, Miller JJJ, Christian HC, Ball V, Santos A, Diaz R, Biggs D, Stillion R, Holdship P, Larner F, Tyler DJ, Clarke K, Davies B, Robbins PA (2015) Cardiac ferroportin regulates cellular iron homeostasis and is important for cardiac function. Proc Natl Acad Sci 112:3164–3169. https://doi.org/10.1073/pnas.1422373112 CrossRefPubMed

43.

Lakhal-Littleton S, Wolna M, Chung YJ, Christian HC, Heather LC, Brescia M, Ball V, Diaz R, Santos A, Biggs D, Clarke K, Davies B, Robbins PA (2016) An essential cell-autonomous role for hepcidin in cardiac iron homeostasis. Elife 5. https://doi.org/10.7554/eLife.19804

44.

Drakesmith H, Schimanski LM, Ormerod E, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, Bastin JM, Cowley D, Chinthammitr Y, Robson KJ, Townsend AR (2005) Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 106:1092–1097. https://doi.org/10.1182/blood-2005-02-0561 CrossRefPubMed

45.

Schimanski LM, Drakesmith H, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, Bastin JM, Cowley D, Chinthammitr Y, Robson KJ, Townsend AR (2005) In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood 105:4096–4102. https://doi.org/10.1182/blood-2004-11-4502 CrossRefPubMed

46.

Anderson CP, Shen M, Eisenstein RS, Leiboldac EA (2012) Mammalian iron metabolism and its control by iron regulatory proteins. Biochim Biophys Acta - Mol Cell Res 1823:1468–1483. https://doi.org/10.1016/J.BBAMCR.2012.05.010

47.

Hentze MW, Muckenthaler MU, Galy B, Camaschella C (2010) Two to tango: regulation of mammalian Iron metabolism. Cell 142:24–38. https://doi.org/10.1016/j.cell.2010.06.028 CrossRefPubMed

48.

Styś A, Galy B, Starzyński RR, Smuda E, Drapier JC, Lipiński P, Bouton C (2011) Iron regulatory protein 1 outcompetes iron regulatory protein 2 in regulating cellular iron homeostasis in response to nitric oxide. J Biol Chem 286:22846–22854. https://doi.org/10.1074/jbc.M111.231902 CrossRefPubMedPubMedCentral

49.

Volz K (2008) The functional duality of iron regulatory protein 1. Curr Opin Struct Biol 18:106–111. https://doi.org/10.1016/j.sbi.2007.12.010

50.

Haddad S, Wang Y, Galy B et al (2016) Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur heart J 38:ehw333. https://doi.org/10.1093/eurheartj/ehw333 CrossRef

51.

Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJV, Anker SD, Ponikowski P (2010) Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 31:1872–1880. https://doi.org/10.1093/eurheartj/ehq158 CrossRefPubMed

52.

Cohen-Solal A, Damy T, Terbah M, Kerebel S, Baguet JP, Hanon O, Zannad F, Laperche T, Leclercq C, Concas V, Duvillié L, Darné B, Anker S, Mebazaa A (2014) High prevalence of iron deficiency in patients with acute decompensated heart failure. Eur J Heart Fail 16:984–991. https://doi.org/10.1002/ejhf.139 CrossRefPubMed

53.

Núñez J, Comín-Colet J, Miñana G, Núñez E, Santas E, Mollar A, Valero E, García-Blas S, Cardells I, Bodí V, Chorro FJ, Sanchis J (2016) Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail 18:798–802. https://doi.org/10.1002/ejhf.513 CrossRefPubMed

54.

Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J (2017) Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail 19(4):522–530. https://doi.org/10.1002/ejhf.640 CrossRefPubMed

55.

Leszek P, Sochanowicz B, Szperl M, Kolsut P, Brzóska K, Piotrowski W, Rywik TM, Danko B, Polkowska-Motrenko H, Różański JM, Kruszewski M (2012) Myocardial iron homeostasis in advanced chronic heart failure patients. Int J Cardiol 159:47–52. https://doi.org/10.1016/j.ijcard.2011.08.006 CrossRefPubMed

56.

Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, Rodenburg RJ, van Veldhuisen DJ, de Boer RA, van der Meer P (2018) Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail 20:910–919. https://doi.org/10.1002/ejhf.1154 CrossRefPubMedPubMedCentral

57.

Kasztura M, Dzięgała M, Kobak K, Bania J, Mazur G, Banasiak W, Ponikowski P, Jankowska EA (2017) Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes. Kardiol Pol 75:267–275. https://doi.org/10.5603/KP.a2016.0155 CrossRefPubMed

58.

Dziegala M, Kasztura M, Kobak K, Bania J, Banasiak W, Ponikowski P, Jankowska EA (2016) Influence of the availability of iron during hypoxia on the genes associated with apoptotic activity and local iron metabolism in rat H9C2 cardiomyocytes and L6G8C5 skeletal myocytes. Mol Med Rep 14:3969–3977. https://doi.org/10.3892/mmr.2016.5705 CrossRefPubMed

59.

Nagao M, Matsuo Y, Kamitani T, Yonezawa M, Yamasaki Y, Kawanami S, Abe K, Mukai Y, Higo T, Yabuuchi H, Takemura A, Yoshiura T, Sunagawa K, Honda H (2014) Quantification of myocardial Iron deficiency in nonischemic heart failure by cardiac T2* magnetic resonance imaging. Am J Cardiol 113:1024–1030. https://doi.org/10.1016/j.amjcard.2013.11.061 CrossRefPubMed

60.

Nagao M, Baba S, Yonezawa M, Yamasaki Y, Kamitani T, Isoda T, Kawanami S, Maruoka Y, Kitamura Y, Abe K, Higo T, Sunagawa K, Honda H (2015) Prediction of adverse cardiac events in dilated cardiomyopathy using cardiac T2* MRI and MIBG scintigraphy. Int J Cardiovasc Imaging 31:399–407. https://doi.org/10.1007/s10554-014-0562-1 CrossRefPubMed

61.

Núñez J, Monmeneu JV, Mollar A, Núñez E, Bodí V, Miñana G, García-Blas S, Santas E, Agüero J, Chorro FJ, Sanchis J, López-Lereu MP (2016) Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study. ESC Hear Fail 3:293–298. https://doi.org/10.1002/ehf2.12101 CrossRef

62.

Terrovitis JV, Kaldara E, Ntalianis A, Sventzouri S, Kapelios C, Barbarousi D, Matsouka C, Nanas JN (2012) Intravenous Iron alone is equally effective with the combination of Iron and erythropoietin for the treatment of Iron-deficiency Anemia in advanced heart failure. J Am Coll Cardiol 60:2255–2256. https://doi.org/10.1016/j.jacc.2012.05.065 CrossRefPubMed

63.

McDonagh T, Macdougall IC (2015) Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Fail 17:248–262. https://doi.org/10.1002/ejhf.236 CrossRefPubMedPubMedCentral

64.

Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E, for the NHLBI Heart Failure Clinical Research Network (2017) Effect of Oral Iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and Iron deficiency. JAMA 317:1958–1966. https://doi.org/10.1001/jama.2017.5427 CrossRefPubMedPubMedCentral

65.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators (2009) Ferric Carboxymaltose in patients with heart failure and Iron deficiency. N Engl J Med 361:2436–2448. https://doi.org/10.1056/NEJMoa0908355 CrossRefPubMed

66.

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD, for the CONFIRM-HF Investigators (2015) Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36:657–668. https://doi.org/10.1093/eurheartj/ehu385 CrossRefPubMed

67.

Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R, Parissis J, Gaudesius G, Mori C, von Eisenhart Rothe B, Greenlaw N, Ford I, Ponikowski P, Anker SD (2013) Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 15:1267–1276. https://doi.org/10.1093/eurjhf/hft099 CrossRefPubMedPubMedCentral

68.

Bolger AP, Bartlett FR, Penston HS, O’Leary J, Pollock N, Kaprielian R, Chapman CM (2006) Intravenous Iron alone for the treatment of Anemia in patients with chronic heart failure. J Am Coll Cardiol 48:1225–1227. https://doi.org/10.1016/j.jacc.2006.07.015 CrossRefPubMed

69.

Toblli JE, Lombraña A, Duarte P, Di Gennaro F (2007) Intravenous Iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50:1657–1665. https://doi.org/10.1016/j.jacc.2007.07.029 CrossRefPubMed

70.

Okonko DO, Grzeslo A, Witkowski T, Mandal AKJ, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P (2008) Effect of intravenous Iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and Iron deficiency. J Am Coll Cardiol 51:103–112. https://doi.org/10.1016/j.jacc.2007.09.036 CrossRefPubMed

71.

Usmanov RI, Zueva EB, Silverberg DS, Shaked M Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 21:236–242

72.

Gaber R, Kotb NA, Ghazy M, Nagy HM, Salama M, Elhendy A (2012) Tissue Doppler and strain rate imaging detect improvement of myocardial function in Iron deficient patients with congestive heart failure after Iron replacement therapy. Echocardiography 29:13–18. https://doi.org/10.1111/j.1540-8175.2011.01532.x CrossRefPubMed

73.

Ke Y, Chen YY, Chang YZ, Duan XL, Ho KP, Jiang DH, Wang K, Qian ZM (2003) Post-transcriptional expression of DMT1 in the heart of rat. J Cell Physiol 196:124–130. https://doi.org/10.1002/jcp.10284 CrossRefPubMed

74.

Zhabyeyev P, Oudit GY (2016) Unravelling the molecular basis for cardiac iron metabolism and deficiency in heart failure. Eur heart J 38:ehw386. https://doi.org/10.1093/eurheartj/ehw386 CrossRef

75.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37:2129–2200. https://doi.org/10.1093/eurheartj/ehw128 CrossRefPubMed

Title: Structural and functional abnormalities in iron-depleted heart
Authors: Kamil A Kobak
Malwina Radwańska
Magdalena Dzięgała
Monika Kasztura
Krystian Josiak
Waldemar Banasiak
Piotr Ponikowski
Ewa A Jankowska
Publication date: 01-03-2019
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 2/2019
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-018-9738-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Structural and functional abnormalities in iron-depleted heart

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2019

Practical guidance on the use of sacubitril/valsartan for heart failure

Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management

The use of hospital-based services by heart failure patients in the last year of life: a discussion paper

Takotsubo syndrome: a neurocardiac syndrome inside the autonomic nervous system

Autonomic regulation device therapy in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials

Updates in heart failure 30-day readmission prevention

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page